Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00034125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms